Literature DB >> 21194983

CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens.

Kenichi Asano1, Ami Nabeyama, Yasunobu Miyake, Chun-Hong Qiu, Ai Kurita, Michio Tomura, Osami Kanagawa, Shin-ichiro Fujii, Masato Tanaka.   

Abstract

The generation of tumor-directed cytotoxic T lymphocytes is considered crucial for the induction of antitumor immunity. To activate these CD8(+) T cells, antigen-presenting cells (APCs) must initially acquire tumor cell-associated antigens. The major source of tumor antigens is dead tumor cells, but little is known about how APCs in draining lymph nodes acquire and crosspresent these antigens. Here we show that CD169(+) macrophages phagocytose dead tumor cells transported via lymphatic flow and subsequently crosspresent tumor antigens to CD8(+) T cells. Subcutaneous immunization with irradiated tumor cells protects mice from syngenic tumor. However, tumor antigen-specific CD8(+) T cell activation and subsequent antitumor immunity are severely impaired in mice depleted with CD169(+) macrophages. Neither migratory dendritic cells (DCs) nor lymph node-resident conventional DCs are essential for the crosspresentation of tumor antigens. Thus, we have identified CD169(+) macrophages as lymph node-resident APCs dominating early activation of tumor antigen-specific CD8(+) T cells.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21194983     DOI: 10.1016/j.immuni.2010.12.011

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  185 in total

Review 1.  Targeting stroma to treat cancers.

Authors:  Boris Engels; Donald A Rowley; Hans Schreiber
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

Review 2.  Studying the mononuclear phagocyte system in the molecular age.

Authors:  Andrew Chow; Brian D Brown; Miriam Merad
Journal:  Nat Rev Immunol       Date:  2011-10-25       Impact factor: 53.106

3.  Lipid-Mediated Targeting with Membrane-Wrapped Nanoparticles in the Presence of Corona Formation.

Authors:  Fangda Xu; Michael Reiser; Xinwei Yu; Suryaram Gummuluru; Lee Wetzler; Björn M Reinhard
Journal:  ACS Nano       Date:  2016-01-06       Impact factor: 15.881

4.  Targeted Delivery of Antigen to Activated CD169+ Macrophages Induces Bias for Expansion of CD8+ T Cells.

Authors:  Landon J Edgar; Norihito Kawasaki; Corwin M Nycholat; James C Paulson
Journal:  Cell Chem Biol       Date:  2018-11-01       Impact factor: 8.116

5.  Interleukin-10 From Marginal Zone Precursor B-Cell Subset Is Required for Costimulatory Blockade-Induced Transplantation Tolerance.

Authors:  Girdhari Lal; Yumi Nakayama; Apoorva Sethi; Amit K Singh; Bryna E Burrell; Neeraja Kulkarni; C Colin Brinkman; Daiki Iwami; Tianshu Zhang; Jonathan S Bromberg
Journal:  Transplantation       Date:  2015-09       Impact factor: 4.939

6.  Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors.

Authors:  Scott N Furlan; Rajakumar Mandraju; Travis Brewer; Kole Roybal; Ty Dale Troutman; Wei Hu; Noah W Palm; Arun Unni; Chandrashekhar Pasare
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

7.  Establishment of tumor-associated immunity requires interaction of heat shock proteins with CD91.

Authors:  Yu Jerry Zhou; Michelle Nicole Messmer; Robert Julian Binder
Journal:  Cancer Immunol Res       Date:  2013-12-31       Impact factor: 11.151

8.  Identification of the cellular sentinels for native immunogenic heat shock proteins in vivo.

Authors:  Michelle Nicole Messmer; Joshua Pasmowitz; Laura Elizabeth Kropp; Simon C Watkins; Robert Julian Binder
Journal:  J Immunol       Date:  2013-09-18       Impact factor: 5.422

9.  Myeloid cell-synthesized coagulation factor X dampens antitumor immunity.

Authors:  Claudine Graf; Petra Wilgenbus; Sven Pagel; Jennifer Pott; Federico Marini; Sabine Reyda; Maki Kitano; Stephan Macher-Göppinger; Hartmut Weiler; Wolfram Ruf
Journal:  Sci Immunol       Date:  2019-09-20

10.  Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy.

Authors:  Masahiro Azuma; Yohei Takeda; Hiroko Nakajima; Haruo Sugiyama; Takashi Ebihara; Hiroyuki Oshiumi; Misako Matsumoto; Tsukasa Seya
Journal:  Oncoimmunology       Date:  2016-05-19       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.